Baker BROS. Advisors LP Increases Stock Position in Viridian Therapeutics, Inc. $VRDN

Posted by Stanley Muller on Jun 18th, 2026

Baker BROS. Advisors LP raised its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN – Free Report) by 13.0% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,971,678 shares of the company’s stock after buying an additional 227,272 shares during the period. Baker BROS. Advisors LP’s holdings in Viridian Therapeutics were worth $61,359,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in VRDN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Viridian Therapeutics by 1.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 49,276 shares of the company’s stock valued at $669,000 after buying an additional 876 shares during the period. Goldman Sachs Group Inc. raised its holdings in shares of Viridian Therapeutics by 33.8% during the first quarter. Goldman Sachs Group Inc. now owns 1,231,092 shares of the company’s stock valued at $16,595,000 after acquiring an additional 310,998 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Viridian Therapeutics by 12.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 130,570 shares of the company’s stock valued at $1,760,000 after acquiring an additional 14,788 shares in the last quarter. Envestnet Asset Management Inc. bought a new position in shares of Viridian Therapeutics during the second quarter valued at approximately $187,000. Finally, Creative Planning bought a new position in shares of Viridian Therapeutics during the second quarter valued at approximately $179,000.

Viridian Therapeutics Stock Up 4.6%

VRDN stock opened at $16.71 on Thursday. Viridian Therapeutics, Inc. has a fifty-two week low of $13.18 and a fifty-two week high of $34.29. The business’s 50 day moving average price is $15.91 and its two-hundred day moving average price is $24.92. The company has a debt-to-equity ratio of 0.10, a quick ratio of 15.15 and a current ratio of 15.15. The company has a market capitalization of $1.72 billion, a price-to-earnings ratio of -5.03 and a beta of 0.90.

Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.90) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.16. Viridian Therapeutics had a negative net margin of 490.31% and a negative return on equity of 80.19%. The business had revenue of $0.14 million for the quarter, compared to analyst estimates of $0.04 million. During the same quarter in the previous year, the firm posted ($0.87) earnings per share. Viridian Therapeutics’s quarterly revenue was up 95.8% on a year-over-year basis. As a group, analysts forecast that Viridian Therapeutics, Inc. will post -3.87 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently commented on VRDN. Wall Street Zen upgraded Viridian Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday. Wells Fargo & Company decreased their target price on Viridian Therapeutics from $29.00 to $20.00 and set an “equal weight” rating for the company in a report on Tuesday, March 31st. The Goldman Sachs Group decreased their target price on Viridian Therapeutics from $36.00 to $31.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. Evercore set a $26.00 target price on Viridian Therapeutics in a report on Friday, May 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Viridian Therapeutics in a report on Monday, April 20th. Twelve research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $36.14.

Get Our Latest Research Report on VRDN

Insider Buying and Selling

In other Viridian Therapeutics news, Director Fairmount Funds Management Llc acquired 1,176,470 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The shares were acquired at an average price of $17.00 per share, with a total value of $19,999,990.00. Following the completion of the purchase, the director directly owned 5,090,928 shares of the company’s stock, valued at approximately $86,545,776. The trade was a 30.05% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 2.40% of the stock is owned by insiders.

Viridian Therapeutics Profile

(Free Report)

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.